Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer

Breast Cancer Research and Treatment

Volumn 140, Issue 1, 2013, Pages 49-61

  Zhou, Yunli ^a   Zhao, Lili ^a   Xiong, Tie ^a   Chen, Xiaojun ^a   Zhang, Yongci ^a   Yu, Man ^a   Yang, Jie ^a   Yao, Zhi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Neurokinin receptors; Substance P; Tachykinins; Tumor metastasis

Indexed keywords

ASN 1377642; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (3 CHLOROPHENYL) 2 (4 PHENYL 5 PYRIDINE 4 YL 4H[1,2,4]TRIAZOL 3 YLSULFANYL)ACETAMIDE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; TUMOR PROMOTION;

ANILINE COMPOUNDS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE; MAMMARY GLANDS, HUMAN; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEUROKININ-1 RECEPTOR ANTAGONISTS; PHOSPHORYLATION; RECEPTORS, NEUROKININ-1; REFERENCE VALUES; SUBSTANCE P; TRIAZOLES;

EID: 84880290905     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2599-6     Document Type: Article

References (40)

1. Hyder SM, Chiappetta C, Stancel GM (2001) Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer 92(4):469-473 (Pubitemid 32319417)
2. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D, Seftor E, Hendrix MJ, Katsanis E, Akporiaye ET (2001) Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int J Cancer 91(1):76-82
3. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50-56 (Pubitemid 32225831)
4. Nawa H, Hirose T, Takashima H, Inayama S, Nakanishi S (1983) Nucleotide sequences of cloned cDNAs for two types of bovine brain substance P precursor. Nature 306(5938):32-36 (Pubitemid 13022759)
5. Kotani H, Hoshimaru M, Nawa H, Nakanishi S (1986) Structure and gene organization of bovine neuromedin K precursor. Proc Natl Acad Sci USA 83(18):7074-7078 (Pubitemid 16002372)
6. Zhang Y, Lu L, Furlonger C, Wu GE, Paige CJ (2000) Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol 1(5):392-397
7. Rozengurt E (2002) Neuropeptide as growth factors for normal and cancerous cells. Trends Endocrinol Metab 13(3):128-134 (Pubitemid 36734003)
8. Muñoz M, Rosso M, Coveñas R (2010) A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr Med Chem 17(6):504-516
9. Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV, Muñoz M (2008) The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol 29(4):245-254
10. Brener S, González-Moles MA, Tostes D, Esteban F, Gil-Montoya JA, Ruiz-Avila I, Bravo M, Muñoz M (2009) A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma. Anticancer Res 29(6):2323-2329
11. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, Haase GM, Black CT, Perez C, Shimada H, Gerbing R, Stram DO, Matthay KK (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21(3):181-189 (Pubitemid 30306028)
12. Oh HS, Moharita A, Potian JG, Whitehead IP, Livingston JC, Castro TA, Patel PS, Rameshwar P (2004) Bone marrow stroma influences transforming growth factor-beta production in breast cancer cells to regulate c-myc activation of the preprotachykinin-I gene in breast cancer cells. Cancer Res 64(17):6327-6336 (Pubitemid 39129438)
13. Lang K, Drell TL 4th, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112(2):231-238 (Pubitemid 39244363)
14. Satake H, Kawada T (2006) Overview of the primary structure, tissue distribution, and functions of tachykinins and their receptors. Curr Drug Targets 7(8):963-974
15. Fong TM, Anderson SA, Yu H, Huang RR, Strader CD (1992) Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol Pharmacol 41(1):24-30
16. Lai JP, Ho WZ, Kilpatrick LE, Wang X, Tuluc F, Korchak HM, Douglas SD (2006) Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation. Proc Natl Acad Sci USA 103(20):7771-7776
17. Rao G, Patel PS, Idler SP, Maloof P, Gascon P, Potian JA, Rameshwar P (2004) Facilitating role of preprotachykinin-I gene in the integration of breast cancer cells within the stromal compartment of the bone marrow: a model of early cancer progression. Cancer Res 64(8):2874-2881 (Pubitemid 38500628)
18. Ramkissoon SH, Patel PS, Taborga M, Rameshwar P (2007) Nuclear factor-κB is central to the expression of truncated neurokinin-1 receptor in breast cancer: implication for breast cancer: implication for breast cancer cell quiescence within bone marrow stroma. Cancer Res 67(4):1653-1659 (Pubitemid 46383391)
19. Gillespie E, Leeman SE, Coukos JA, O'Brien MJ, Cerda SR, Farraye FA, Stucchi AF, Becker JM (2011) Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer. Proc Natl Acad Sci USA 108(42):17420-17425
20. Patel HJ, Ramkissoon SH, Patel PS, Rameshwar P (2005) Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proc Natl Acad Sci USA 102(48):17436-17441 (Pubitemid 41740884)
21. Lai JP, Lai S, Tuluc F, Tansky MF, Kilpatrick LE, Leeman SE, Douglas SD (2008) Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc Natl Acad Sci USA 105(34):12605-12610
22. Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C, Zimmermann A, Reubi JC, Büchler MW (2003) Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 83(5):731-742 (Pubitemid 36618051)
23. Horstmann S, Kahle PJ, Borasio GD (1998) Inhibitors of p38 mitogen activated protein kinase promote neuronal survival in vitro. J Neurosci Res 52(4):483-490 (Pubitemid 28259115)
24. Seegers HC, Hood VC, Kidd BL, Cruwys SC, Walsh DA (2003) Enhancement of angiogenesis by endogenous substance P release and neurokinin-1 receptors during neurogenic inflammation. J Pharmacol Exp Ther 306(1):8-12 (Pubitemid 36734351)
25. Khawaja AM, Rogers DF (1996) Tachykinins: receptor to effector. Int J Biochem Cell Biol 28(7):721-738 (Pubitemid 26181860)
26. Maggi CA, Schwartz TW (1997) The dual nature of the tachykinin NK1 receptor. Trends Pharmacol Sci 18(10):351-362 (Pubitemid 27435057)
27. Horstmann S, Kahle PJ, Borasio GD (1998) Inhibitors of p38 mitogen activated protein kinase promote neuronal survival in vitro. J Neurosci Res 52(4):483-490 (Pubitemid 28259115)
28. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270(5240):1326-1331
29. Böhm SK, Khitin LM, Smeekens SP, Grady EF, Payan DG, Bunnett NW (1997) Identification of potential tyrosine containing endocytic motifs in the carboxyl-tail and seventh transmembrane domain of the neurokinin 1 receptor. J Biol Chem 272(4):2363-2372 (Pubitemid 27058524)
30. Li H, Leeman SE, Slack BE, Hauser G, Saltsman WS, Krause JE, Blusztajn JK, Boyd ND (1997) A substance P (neurokinin-1) receptor mutant carboxyl-terminally truncated to resemble a naturally occurring receptor isoform displays enhanced responsiveness and resistance to desensitization. Proc Natl Acad Sci USA 94(17):9475-9480 (Pubitemid 27357854)
31. Nowicki M, Ostalska-Nowicka D, Kondraciuk B, Miskowiak B (2007) The significance of substance P in physiological and malignant haematopoiesis. J Clin Pathol 60(7):749-755 (Review) (Pubitemid 47056902)
32. Böckmann S (2002) Substance P (NK1) receptor expression by human colonic epithelial cell line Caco-2. Peptides 23(10):1783-1791 (Pubitemid 35279837)
33. Muñoz M, Rosso M, Pérez A, Coveñas R, Rosso R, Zamarriego C, Piruat JI (2005) The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 39(4):427-432 (Pubitemid 41073623)
34. Muñoz M, Pérez A, Rosso M, Zamarriego C, Rosso R (2004) Antitumoral action of the neurokinin-1 receptor antagonist L-733060 on human melanoma cell lines. Melanoma Res 14(3):183-188 (Pubitemid 38879579)
35. Muñoz M, Rosso M, Robles-Frias MJ, Salinas-Martín MV, Rosso R, González-Ortega A, Coveñas R (2010) The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 90(8):1259-1269
36. Lang K, Drell TL 4th, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112(2):231-238 (Pubitemid 39244363)
37. Muñoz M, Rosso M, Coveñas R, Montero I, González-Moles MA, Robles MJ (2005) Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138. Invest Ophthalmol Vis Sci 48(6):2775-2781
38. Chernova I, Lai JP, Li H, Schwartz L, Tuluc F, Korchak HM, Douglas SD, Kilpatrick LE (2009) Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R). J Leukoc Biol 85(1):154-164
39. Monaco-Shawver L, Schwartz L, Tuluc F, Guo CJ, Lai JP, Gunnam SM, Kilpatrick LE, Banerjee PP, Douglas SD, Orange JS (2011) Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor. J Leukoc Biol 89(1):113-125
40. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V (2000) Moleculer classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795):536-540 (Pubitemid 30625740)